Top-News
Pharmazeutika USA

Rigel Pharmaceuticals News

Aktie
WKN:  766093 ISIN:  US7665596034 US-Symbol:  RIGL
0,911 €
+0,0425 €
+4,89%
31.05.24 19:54:34
Handeln Depot/Watchlist
Aktienanzahl *
173,67 Mio.
Marktkapitalisierung *
156,53 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 01.06.2023

Rigel Pharmaceuticals News

30.05.24 - PR Newswire
Rigel to Present at the Jefferies Global Healthcare Conference
Rigel to Present at the Jefferies Global Healthcare Conference PR Newswire
23.05.24 - PR Newswire
Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress PR Newswire
07.05.24 - PR Newswire
Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
Rigel Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire
30.04.24 - PR Newswire
Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update
Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update PR Newswire
10.04.24 - PR Newswire
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire
04.04.24 - PR Newswire
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-​Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma PR Newswire
12.03.24 - PR Newswire
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer PR Newswire
05.03.24 - PR Newswire
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update PR Newswire
27.02.24 - PR Newswire
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update PR Newswire
22.02.24 - PR Newswire
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO® PR Newswire
08.01.24 - PR Newswire
Rigel Pharmaceuticals Provides Business Update
Rigel Pharmaceuticals Provides Business Update PR Newswire
05.01.24 - PR Newswire
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire
04.01.24 - PR Newswire
Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma
Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma PR Newswire
03.01.24 - PR Newswire
Rigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire
08.12.23 - PR Newswire
Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other Cancers
Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other Cancers PR Newswire
07.11.23 - PR Newswire
Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update
Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update PR Newswire
06.11.23 - PR Newswire
Rigel to Present at the Jefferies London Healthcare Conference
Rigel to Present at the Jefferies London Healthcare Conference PR Newswire
02.11.23 - PR Newswire
Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition
Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition PR Newswire
31.10.23 - PR Newswire
Rigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business Update
Rigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business Update PR Newswire
11.10.23 - PR Newswire
Rigel Announces Presentation at the Upcoming IDWeek 2023
Rigel Announces Presentation at the Upcoming IDWeek 2023 PR Newswire

Newssuche

Videos

newspaper
29.05.24 +31,94%
Technical Trading: DAX Long Chance kurzfristig
DAX Long Typ: Turbo Open End WKN: VD5FWS Hebel: 28 Laufzeit: OpenEnd Einstieg: Market ... Mehr »